Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.2.1.31 (beta-glucuronidase)
 7,680 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The concentration of 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), kallikrein-like enzymes and beta-glucuronidase were quantified in the cerebrospinal fluid (CSF) during spontaneous migraine attacks. Plasma levels of kallikrein-like enzymes and beta-glucuronidase, as well as urinary levels of 5-HIAA as free acid and glucuronides were also measured. Correlation of these biochemical findings with various clinical variables showed that 5-HIAA in the CSF did not correlate with either the time sequences of migraine attacks or with clinical division of migraine into classical and common migraine. CSF 5-HIAA correlated positively with HVA, EEG photostimulation, the triggering of food and the therapeutic effect of the so-called antiserotonin treatment, and negatively with esterase activity. Urinary 5-HIAA showed a significant increase during the early headache stage.
 ...
PMID:Changes in serotonin metabolism during migraine attacks. 97 98

Glycosaminoglycan polysulfate (GAGPS = Arteparon) is used for the treatment of degenerative joint diseases; it inhibits enzymes that dissociate ground substance, e.g. hyaluronidase, beta-glucuronidase, and acid phosphatase. In turn, an improved synthesis of hyaluronate from the synovial lining cells to hyaluronic acid increases viscosity (Verbruggen and Veys 1977). From January 1975 to December 1979, in the Orthopedic Division of the Clinic "St. Elizabeth" in Saarlouis, West-Germany, we treated 754 patients with a total of approximately 8000 intra-articular injections of Arteparon. The problem with drugs influencing the metabolism of joint cartilage is that the results cannot - for obvious reasons - be as conspicuous as e.g. with corticoid injections, although the latter sometimes involve also marked side-effects. After several courses of therapy, on the other hand, the cartilage-protective effect of Arteparon becomes apparent, with an effect lasting for several months. The indications to include the patients into our study were: arthrosis and other cartilage disorders that had been diagnosed prior to onset of therapy by means of either X-ray, surgery, arthrography etc. Therapeutic results were measured by the parameters: subsidence of pain, recession of edema, improved joint motion, etc. Arteparon, applied intra-articularly, was well tolerated; local irritation, and swelling of the treated joints were reported in only 4.7% of the treated cases; the therapeutic overall result was good. Occasionally, a case of headache was observed, however, no case of joint infection was reported.
 ...
PMID:[Clinical studies of intra-articular injections of Arteparon. Retrospective study following the treatment of 754 patients]. 621 39

Several controlled clinical trials have shown that specific immunotherapy (SIT) using incremental injections of allergens can be effective in the treatment of allergic rhinitis and asthma. Nevertheless, the risk of side effects have led to some recommended limitations of SIT. Enzyme-potentiated desensitization (EPD) is a proposed method for immunotherapy with very low doses of mixed allergens plus beta-glucuronidase enzyme, for which irrelevant or no side effects have been claimed. The aim of this study was to determine the clinical efficacy of EPD in the treatment of pollinosis. A double-blind placebo-controlled trial of EPD among 20 patients sensitive to Parietaria and grass pollen was performed. All patients recorded daily symptom scores for nine months following a single intradermal injection of EPD or buffered saline received in February. Symptoms recorded were nasal itching and obstruction, sneezing, rhinorrhea, itchy eyes and excessive tear production. Moreover, total and specific lgE were measured and CD3+, CD4+ and CD8+ peripheral blood lymphocytes were counted at different times. In the same period, ten additional subjects, with an allergic clinical profile similar to the subjects admitted to the double-blind trial, were studied in an open clinical trial in order to evaluate the effects of EPD without enzyme using a mixture of allergens. Symptom scores were higher in the placebo group (p < 0.001), with a similar level of significance for both global symptom score and for each individual symptom. Active-treated patients had a significant post-treatment increase in the mean percentage of T-CD8+ peripheral blood cells and a significant post-seasonal decrease in the mean percentage of Parietaria specific lgE. On the contrary, placebo-treated patients had a borderline significant post-seasonal decrease in the mean percentage of CD8+ circulating cells and a significant seasonal increase in the mean percentage of Parietaria specific lgE with no significant post-seasonal decrease. Finally, clinical results of the mixture of allergens injection were similar to those of the placebo in the double-blind trial. EPD injection caused only an asymptomatic, local wheal and flare lasting about two hours. Two patients (20%) in the active-treated group experienced a delayed, mild, unusual headache lasting about two days. In conclusion, EPD is clinically effective in the treatment of pollinosis. Some immunological modifications observed in the EPD-treated patients suggest an EPD-induced enhancement of tolerogenic mechanisms like "immune deviation."
 ...
PMID:Effects of enzyme-potentiated desensitization in the treatment of pollinosis: a double-blind placebo-controlled trial. 884 2